Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study

T. Tsuboi, Robert Bies, T. Suzuki, H. Takeuchi, S. Nakajima, A. Graff-Guerrero, D. C. Mamo, F. Caravaggio, E. Plitman, M. Mimura, B. G. Pollock, H. Uchida

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Due to high inter-individual variability in peripheral pharmacokinetic parameters, dosing of antipsychotics currently relies on clinical trial-and-error, and predicting antipsychotic plasma concentrations before changing a dose has been a challenge. Methods: Patients with schizophrenia receiving a stable dose of olanzapine were included. 2 plasma samples were collected at 2 given time points for the measurement of plasma olanzapine concentrations. At least 7 days after a dosage change of olanzapine, a third sample was collected. The plasma concentration of the third sample was predicted in a blinded fashion using a mixed-effects model with NONMEM®, using the following information: the 2 baseline plasma concentrations, the interval between the last dose and blood draw, and clinical and demographic information. Results: 31 subjects (mean±SD age=56.0±11.6; 19 men) were enrolled. The mean prediction (95% confidence interval) errors were 1.6 (-2.8 to 6.0) ng/mL. A highly significant correlation was observed between the observed and predicted concentrations of the third sample (r=0.91, p

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalPharmacopsychiatry
Volume48
Issue number7
DOIs
StatePublished - Oct 27 2015

Fingerprint

olanzapine
Pharmacokinetics
Population
Antipsychotic Agents
Schizophrenia
Demography
Clinical Trials
Confidence Intervals

Keywords

  • olanzapine
  • plasma concentration
  • population pharmacokinetics
  • therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Predicting Plasma Olanzapine Concentration Following a Change in Dosage : A Population Pharmacokinetic Study. / Tsuboi, T.; Bies, Robert; Suzuki, T.; Takeuchi, H.; Nakajima, S.; Graff-Guerrero, A.; Mamo, D. C.; Caravaggio, F.; Plitman, E.; Mimura, M.; Pollock, B. G.; Uchida, H.

In: Pharmacopsychiatry, Vol. 48, No. 7, 27.10.2015, p. 286-291.

Research output: Contribution to journalArticle

Tsuboi, T, Bies, R, Suzuki, T, Takeuchi, H, Nakajima, S, Graff-Guerrero, A, Mamo, DC, Caravaggio, F, Plitman, E, Mimura, M, Pollock, BG & Uchida, H 2015, 'Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study', Pharmacopsychiatry, vol. 48, no. 7, pp. 286-291. https://doi.org/10.1055/s-0035-1565070
Tsuboi, T. ; Bies, Robert ; Suzuki, T. ; Takeuchi, H. ; Nakajima, S. ; Graff-Guerrero, A. ; Mamo, D. C. ; Caravaggio, F. ; Plitman, E. ; Mimura, M. ; Pollock, B. G. ; Uchida, H. / Predicting Plasma Olanzapine Concentration Following a Change in Dosage : A Population Pharmacokinetic Study. In: Pharmacopsychiatry. 2015 ; Vol. 48, No. 7. pp. 286-291.
@article{002c142b210e4d1dbd18553723bb424c,
title = "Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study",
abstract = "Introduction: Due to high inter-individual variability in peripheral pharmacokinetic parameters, dosing of antipsychotics currently relies on clinical trial-and-error, and predicting antipsychotic plasma concentrations before changing a dose has been a challenge. Methods: Patients with schizophrenia receiving a stable dose of olanzapine were included. 2 plasma samples were collected at 2 given time points for the measurement of plasma olanzapine concentrations. At least 7 days after a dosage change of olanzapine, a third sample was collected. The plasma concentration of the third sample was predicted in a blinded fashion using a mixed-effects model with NONMEM{\circledR}, using the following information: the 2 baseline plasma concentrations, the interval between the last dose and blood draw, and clinical and demographic information. Results: 31 subjects (mean±SD age=56.0±11.6; 19 men) were enrolled. The mean prediction (95{\%} confidence interval) errors were 1.6 (-2.8 to 6.0) ng/mL. A highly significant correlation was observed between the observed and predicted concentrations of the third sample (r=0.91, p",
keywords = "olanzapine, plasma concentration, population pharmacokinetics, therapeutic drug monitoring",
author = "T. Tsuboi and Robert Bies and T. Suzuki and H. Takeuchi and S. Nakajima and A. Graff-Guerrero and Mamo, {D. C.} and F. Caravaggio and E. Plitman and M. Mimura and Pollock, {B. G.} and H. Uchida",
year = "2015",
month = "10",
day = "27",
doi = "10.1055/s-0035-1565070",
language = "English (US)",
volume = "48",
pages = "286--291",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "7",

}

TY - JOUR

T1 - Predicting Plasma Olanzapine Concentration Following a Change in Dosage

T2 - A Population Pharmacokinetic Study

AU - Tsuboi, T.

AU - Bies, Robert

AU - Suzuki, T.

AU - Takeuchi, H.

AU - Nakajima, S.

AU - Graff-Guerrero, A.

AU - Mamo, D. C.

AU - Caravaggio, F.

AU - Plitman, E.

AU - Mimura, M.

AU - Pollock, B. G.

AU - Uchida, H.

PY - 2015/10/27

Y1 - 2015/10/27

N2 - Introduction: Due to high inter-individual variability in peripheral pharmacokinetic parameters, dosing of antipsychotics currently relies on clinical trial-and-error, and predicting antipsychotic plasma concentrations before changing a dose has been a challenge. Methods: Patients with schizophrenia receiving a stable dose of olanzapine were included. 2 plasma samples were collected at 2 given time points for the measurement of plasma olanzapine concentrations. At least 7 days after a dosage change of olanzapine, a third sample was collected. The plasma concentration of the third sample was predicted in a blinded fashion using a mixed-effects model with NONMEM®, using the following information: the 2 baseline plasma concentrations, the interval between the last dose and blood draw, and clinical and demographic information. Results: 31 subjects (mean±SD age=56.0±11.6; 19 men) were enrolled. The mean prediction (95% confidence interval) errors were 1.6 (-2.8 to 6.0) ng/mL. A highly significant correlation was observed between the observed and predicted concentrations of the third sample (r=0.91, p

AB - Introduction: Due to high inter-individual variability in peripheral pharmacokinetic parameters, dosing of antipsychotics currently relies on clinical trial-and-error, and predicting antipsychotic plasma concentrations before changing a dose has been a challenge. Methods: Patients with schizophrenia receiving a stable dose of olanzapine were included. 2 plasma samples were collected at 2 given time points for the measurement of plasma olanzapine concentrations. At least 7 days after a dosage change of olanzapine, a third sample was collected. The plasma concentration of the third sample was predicted in a blinded fashion using a mixed-effects model with NONMEM®, using the following information: the 2 baseline plasma concentrations, the interval between the last dose and blood draw, and clinical and demographic information. Results: 31 subjects (mean±SD age=56.0±11.6; 19 men) were enrolled. The mean prediction (95% confidence interval) errors were 1.6 (-2.8 to 6.0) ng/mL. A highly significant correlation was observed between the observed and predicted concentrations of the third sample (r=0.91, p

KW - olanzapine

KW - plasma concentration

KW - population pharmacokinetics

KW - therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=84948105798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948105798&partnerID=8YFLogxK

U2 - 10.1055/s-0035-1565070

DO - 10.1055/s-0035-1565070

M3 - Article

C2 - 26506574

AN - SCOPUS:84948105798

VL - 48

SP - 286

EP - 291

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 7

ER -